Cheshire and Merseyside Strategic Clinical Networks Local Issues and Challenges 22 nd May 2015.

Slides:



Advertisements
Similar presentations
Early Diagnosis and Primary Care
Advertisements

Di Riley Associate Director, Clinical Outcomes NCIN
Reinventing Cancer Support Ciarán Devane Chief Executive.
Shaping a blueprint for cancer Plymouth Cancer Summit Sean Duffy February 2015.
March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
C.I.A. ?. Central Intelligence Agency Cardiff International Arena Cost Impact Analysis Cotton Insurance Association Cheers in Advance Circumcision Information.
Trust Cancer Lead Clinician
The LCA: Implementing a Quality Assurance and Informatics Strategy to Enhance Cancer Care Dr Shelley Dolan LCA Clinical Director.
The National Cancer Intelligence Network An overview Professor David Forman Professor of Cancer Epidemiology, University of Leeds NCIN – Lead for Information.
How is place of death for cancer patients changing and what affects it? UKACR Conference September 28 th 2004 Elizabeth Davies Karen Linklater Ruth Jack.
Variations in Cancer Surgery Across the East Midlands and North Trent EMPHIN Forum (Apr 2010) Carolynn Gildea Trent Cancer Registry.
Evidence for the benefit of cancer multidisciplinary working Professor Amanda J Ramirez Director of the KCL Promoting Early Presentation Group & National.
What’s on the Horizon Anita Corrigan Nurse Director
Chester Ellesmere Port & Neston Rural Making sure you get the healthcare you need West Cheshire CCG Strategy Dr Andy McAlavey Medical Director West Cheshire.
Macmillan GP Facilitator for Walsall Dr Joo Ee Teoh, St Peter’s Surgery.
Linda Devereux Associate Director Merseyside and Cheshire Cancer Network - why we are here and what’s next!
AAACM – what’s going on with the trend in LCR…? …and can it be explained by cancer?
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
Delivering clinical research to make patients, and the NHS, better Cancer Patients’ Experiences of Research Findings from the National Cancer Patient Experience.
National Cancer Intelligence Network data usage 17 November 2015 – Veronique Poirier – Principal Cancer Analyst – NCIN.
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
Delivering clinical research to make patients, and the NHS, better Cancer Patients’ Experiences of Research Findings from the National Cancer Patient Experience.
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
What data are available, and how are they accessed?
National Cancer Intelligence Network What data are available, and how are they accessed? Cancer Roadshow (London) 13 th April 2015 Vivian Mak, Information.
The national context for cancer intelligence. National Cancer Intelligence Network.
South West Public Health Observatory South West Regional Public Health Group Prostate cancer in England and the South West Sean McPhail 1, Paul Eves 1,
What data are collected? How, and who by? Karen Graham and Barry Plewa.
NCIN Roadshow: Cancer Data NCIN - Cancer Data Roadshow Public Health England | 2015 Elsita Payne Head of Registration – East Midlands and North West Branches.
Trends in prostate cancer and its management in the South West Region, Hampshire and the Isle of Wight Christine Harling Julia Verne (SWPHO) Roy Maxwell.
What does the cancer landscape look like now? - The national context for cancer intelligence Jason Poole, Deputy Head (Local Interface), National Cancer.
Where can I find data on cancer? Victoria H Coupland London Knowledge and Intelligence Team 20 February 2014.
What does the cancer intelligence landscape look like now? Dr Mick Peake Clinical Lead, National Cancer Intelligence Network.
COSD Roadshow Local Issues and Challenges Hilary Wilderspin; London Cancer Alliance 13 th April 2015 v2.
What data are available, and how are they accessed?
Uses of Cancer Data by RTPCT Cancer Chapter of the Public Health Annual Report 2003 Dr José M Ortega.
How clinicians use data to make an impact on clinical outcomes Dr Mick Peake Clinical Lead, National Cancer Intelligence Network Consultant & Senior Lecturer.
What data are collected? How, and who by?. It’s complicated… ONS data.
Cancer - What’s available from the LHO? David Hofman.
East Midlands Strategic Clinical Networks & Senate Cancer Roadshow.
Prostate cancer and socio-economic deprivation When PCTs are ranked according to their income score using the Indices of Multiple Deprivation (IMD)* there.
Introduction to the National End of Life Care Intelligence Network Professor Julia Verne Clinical Lead – National End of Life Care Intelligence Network.
South West Public Health Observatory South West Regional Public Health Group Overview of Neuro-oncology in the South West Sean McPhail South West Public.
Oesophago–Gastric Cancer Audit
How clinicians use data to make an impact on clinical outcomes
Delivery of systemic therapy in Gloucestershire for NSCLC
July 2016 update from the National Cancer Registration and Analysis Service Local The NCRAS Local Group for Intelligence on Cancer (LoGIC), a group of.
National Oesophago–Gastric Cancer Audit 2015.
CNC Orientation Forum May 2013
Prepared by staff in Prevention and Cancer Control.
Jane E Scullion Respiratory Nurse Consultant
Segmented analysis of prostate cancer pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Oesophago–Gastric Cancer
Review of NLCA cases detected through non –COSD routes 2016
Dr James Carlton, Medical Adviser
Lung Cancer Audit to patient Reference Group
Treatment breakdown for prostate cancers
All Cancers Excluding Non-Melanoma Skin Cancer (C00-C97 Excl
Primary care engagement Programme
National Lung Cancer Audit
Segmented analysis of the lung cancer median pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Pathway for patients with suspected Upper GI (OG) Cancer
National Cancer Diagnosis Audit
Inquiry into geographical inequalities in breast cancer
Making MDTs better Steve Falk
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
Early Diagnosis Diagnostics Cancer Waits Survivorship South West Cancer Network 14 November 2014.
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
MDT scorecard – using routine data to reduce unwarranted variations
Presentation transcript:

Cheshire and Merseyside Strategic Clinical Networks Local Issues and Challenges 22 nd May 2015

Primary Causes of Death in Cheshire & Merseyside 2013 Data Source: ONS

Top 5 Cancer Deaths Age standardised mortality rate – 2012 for Cheshire and Merseyside Data Source: PHE, Cancer Analysis System, NCIN Cancer Commissioning Toolkit/charts

Cancer Care: Cancer Commissioning Toolkit : Key Points Cheshire and Merseyside have lower income deprivation scores and high percentages of residents aged 75 and over There are 2,991 people aged 75 and over living for years after their cancer diagnosis Cancer incidence and mortality trends follow the national trend but are higher Data Source: National Cancer Intelligence Network

Lung, Upper GI, Urology, Lower GI and Breast Cancers have the highest mortality rates with this network Surgery for confirmed cases of Non-Small Cell Lung Cancer is in the top 20 highest in the country (based in 7 Trust Multidisciplinary Team (MDTs) ) Cancer Care: Cancer Commissioning Toolkit : Key Points Data Source: National Cancer Intelligence Network

COSD is the source of data being used for National outcome measures; survival by stage, SACT mortality National audits including clinician level data; prostate and lung Clinical indicators for each tumour type use in peer review assessments which will be available to the CQC COSD within the Network

Ensuring high quality cancer data capture and reporting To increase data completeness for CNS coding To understand the reasons for variation in the network To improve patient experience by looking at tumour specific pathways Challenges